Developing Next Generation Agents
for Psychedelic Therapy

Lophora is a clinical-stage biotech company developing novel, next generation
psychedelic agents to treat a multitude of psychiatric disorders

About us

Founded in 2018 Lophora has successfully finished initial characterization of its lead-candidate through funding granted by the BioInovation institute (Novo Nordisk Foundation) and will initiate first-in-human trials by 2024